Networks of Innovation

Vaccine Development at Merck, Sharp and Dohme, and Mulford, 1895-1995
Erscheinungsjahr 1996
ISBN: 978-0-521-56308-6
Verlag: Cambridge University Press

Buch, Englisch, 320 Seiten, Format (B × H): 157 mm x 235 mm, Gewicht: 517 g

Networks of Innovation offers an historical perspective on the manner in which private-sector organizations have acquired, sustained, and periodically lost the ability to develop, manufacture, and market new serum antitoxins and vaccines. The primary focus is on the H. K. Mulford Company, on Sharp and Dohme, which acquired Mulford in 1929, and upon Merck & Co Inc., which merged with Sharp and Dohme in 1953. By surveying a century of innovation in biologicals, the authors are able to analyze the conditions that either promoted or prevented creative changes in this important industry. They show how the activities of these three commercial enterprises were related to a series of complex, evolving networks of scientific, governmental, and medical institutions in the United States and abroad. This is the first such history to draw exclusively on sources internal to Merck, one of the world's leading innovators in modern vaccines and pharmaceuticals.

Autoren/Hrsg.

Galambos, Louis

Sewell, Jane Eliot

Weitere Mitwirkende

Eliot Sewell, Jane

Inhaltsverzeichnis

Preface; 1. 1894: 'The foremost medical question of the day'; 2. The Mulford story; 3. A Sharp & Dohme interlude; 4. The virology network and a new programme at Merck, Sharp & Dohme; 5. Hilleman's innovations: first phase, measles-mumps-rubella; 6. Dangerous interlude, Marek's Disease adjuvant 65, the Swine Flu drama; 7. Transforming bacteriology: a second phase, meningitis, pneumonia, haemophilus, influenzae; 8. New networks, new leadership: the Hepatitis B vaccines; 9. Vaccine innovation in the nineties: new strategies, new structures, and public confrontations; A word about sources.